Cargando…
Progress in targeted therapy for breast cancer
Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Medical Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160667/ https://www.ncbi.nlm.nih.gov/pubmed/30276363 http://dx.doi.org/10.1016/j.cdtm.2018.04.002 |
_version_ | 1783358815531433984 |
---|---|
author | Ju, Jie Zhu, An-Jie Yuan, Peng |
author_facet | Ju, Jie Zhu, An-Jie Yuan, Peng |
author_sort | Ju, Jie |
collection | PubMed |
description | Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems. |
format | Online Article Text |
id | pubmed-6160667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Chinese Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-61606672018-10-01 Progress in targeted therapy for breast cancer Ju, Jie Zhu, An-Jie Yuan, Peng Chronic Dis Transl Med Perspective Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems. Chinese Medical Association 2018-07-07 /pmc/articles/PMC6160667/ /pubmed/30276363 http://dx.doi.org/10.1016/j.cdtm.2018.04.002 Text en © 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Perspective Ju, Jie Zhu, An-Jie Yuan, Peng Progress in targeted therapy for breast cancer |
title | Progress in targeted therapy for breast cancer |
title_full | Progress in targeted therapy for breast cancer |
title_fullStr | Progress in targeted therapy for breast cancer |
title_full_unstemmed | Progress in targeted therapy for breast cancer |
title_short | Progress in targeted therapy for breast cancer |
title_sort | progress in targeted therapy for breast cancer |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160667/ https://www.ncbi.nlm.nih.gov/pubmed/30276363 http://dx.doi.org/10.1016/j.cdtm.2018.04.002 |
work_keys_str_mv | AT jujie progressintargetedtherapyforbreastcancer AT zhuanjie progressintargetedtherapyforbreastcancer AT yuanpeng progressintargetedtherapyforbreastcancer |